Publications by authors named "M Gawkowska-Suwinska"
Background And Purpose: To evaluate high-dose-rate brachytherapy (HDR BT) as a salvage modality for locally recurrent prostate cancer after primary radiotherapy failure.
Materials And Methods: Eighty-three prostate cancer patients, who locally relapsed after radiotherapy, were treated with salvage HDR BT. The schedule was three implantations, every two weeks, with 10Gy per implant, to a total dose of 30Gy.
Objective: There is disagreement regarding the value of the α/β ratio for prostate cancer. Androgen deprivation therapy (ADT) may dominate the effects of dose fractionation on prostate-specific antigen (PSA) response and confound estimates of the α/β ratio. We estimate this ratio from combined data on external beam radiation therapy (EBRT) and brachytherapy (BT)-treated patients, providing a range of doses per fraction, while accounting for the effects of ADT.
View Article and Find Full Text PDFArticle Synopsis
- Certain inherited gene variations related to tumor growth and blood vessel formation may impact cancer treatment outcomes and prognosis.
- Researchers studied the effects of specific genetic polymorphisms in several genes on survival rates of 350 Caucasian patients with inoperable non-small cell lung cancer (NSCLC).
- The study found that specific genetic variations (like those in VEGFR2 and COX-2) are associated with poorer overall and progression-free survival, suggesting these variations could be used as potential markers for prognosis in NSCLC patients undergoing treatment.
Background: Clinical data that compare external-beam radiotherapy (EBRT) combined with high-dose-rate brachytherapy (HDR-BT) boost versus EBRT alone are scarce. The analysis of published studies suggest that biochemical relapse-free survival in combined EBRT and HDR-BT may be superior compared to EBRT alone. We retrospectively examined the effectiveness and tolerance of both schemes in a single center study.
View Article and Find Full Text PDFAim: To evaluate the tolerability and toxicity of PCI in patients with NSCLC.
Background: Prophylactic cranial irradiation (PCI) is a standard treatment for patients with small cell lung cancer. There are data showing a decreasing ratio of brain metastases after PCI for non-small cell lung cancer (NSCLC-non small cell lung cancer) patients but, so far, there is no evidence for increasing overall survival.